ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

DeVita Resigns As No. 2 At Sloan-Kettering To “Pursue Clinical Research,” Hospital Says

May 31, 1991

Newest NIH Institute, NIBIB, Gets An Acting Director.

May 11, 2001

In Brief: Cancer Panel To Meet In Seattle, Houston, Chicago; Wisconsin’s Robert Johnson Dies; Goldin Retires

August 27, 1982

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

NCAB Working Group To Hold Open And Closed Sessions

January 20, 1995

In Their Own Words: A 64-page Internal Report with over 1,500 Faculty Comments on MD Anderson Morale

March 29, 2013